About CRISPR Therapeutics AG - Common Shares (CRSP)
Crispr Therapeutics is a biopharmaceutical company that focuses on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing technology. The company aims to harness the potential of genetic editing to treat various conditions, including genetic disorders, cancer, and autoimmune diseases. Through a combination of innovative research and strategic collaborations, Crispr Therapeutics is dedicated to advancing its pipeline of therapies and ultimately improving patient outcomes and quality of life. Read More
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as the linchpin in the quest to develop cures for a myriad of debilitating diseases. This significant investment is poised to revolutionize how scientists approach genetic disorders, moving beyond [...]
Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam Therapeutics.
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central theme at the recent Quarter Century Update conference, where leading experts like Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, illuminated how AI is [...]
Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the time. Every now and then, though, the right opportunity comes along.
As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for sustainability. This dynamic landscape is giving rise to several high-growth sectors that are not only reshaping industries but also presenting unprecedented investment opportunities.
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving market demands. New drug developments, particularly in sophisticated biologics, groundbreaking gene therapies, and blockbuster obesity treatments, are fundamentally altering therapeutic paradigms. Simultaneously, the pervasive integration of
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.
